Treats hallucinations and delusions associated with Parkinson’s disease psychosis. ANDA 214925, held by MSN Laboratories. Pimavanserin Tartrate.
As of Nov 22, 2026, ANDA 214925 (Pimavanserin), held by MSN Laboratories, was first approved by FDA on Jan 16, 2024, with 0 approved supplements and 0 published complete response letters.
Pimavanserin capsule is indicated for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 16, 2024 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| PimavanserinEQ 34MG BASE · capsule;oral | Pimavanserin Tartrate | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters